Echo Therapeutics Announces Positive Results of a Clinical Study of its Transdermal Continuous Glucose Monitoring System

31-Jul-2008

Echo Therapeutics announced positive results of a clinical study of its Symphony(TM) Transdermal Continuous glucose Monitoring (tCGM) System in patients with Type 1 and Type 2 diabetes. Echo's non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and the Prelude(TM) SkinPrep System, which incorporates leading-edge, needle-free skin permeation control. Echo's Symphony tCGM System is designed to provide both diabetics and hospital patients with a reliable, affordable, comfortable-to-wear, and easy-to-use, needle-free continuous glucose monitoring device.

"This study represents another major advancement in our Prelude and Symphony development programs," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We have now successfully used Prelude, our new needle-free skin preparation system, in combination with our non-invasive Symphony tCGM technology. Data from this study demonstrate that Symphony, using Prelude, is safe, accurate and reliable at monitoring glucose levels. We look forward to continuing progress with our Symphony development program throughout the year."

After Prelude skin permeation, Symphony tCGM biosensors were applied to ten subjects with Type 1 or Type 2 diabetes. Venous reference blood samples were taken from intravenous lines at 15-minute intervals for 24 hours and measured on a YSI 2300STAT PLUS laboratory analyzer. At the conclusion of the 24-hour observation period, the test skin sites were inspected for redness or any other undesirable effects.

https://www.analytica-world.com/en/news/85278/echo-therapeutics-announces-positive-results-of-a-clinical-study-of-its-transdermal-continuous-glucose-monitoring-system.html